National Institute for Health Development
Department of Epidemiology and Biostatistics 09.06.2017

Cancer survival in Estonia 2010–2014

Estonian Cancer Registry data on all cases of malignant tumours diagnosed in adults (age ≥15 years) in Estonia were included in the analysis (death certificate only and autopsy cases excluded). Relative survival ratios were calculated as the ratio of the observed survival of cancer patients and the expected survival of the underlying general population (1). The latter was calculated according to the Ederer II method (2) using national life tables for Estonian population stratified by gender, age and calendar year. Period analysis was used to estimate relative survival for 2010–2014 (3,4).

One-year and five-year relative survival in Estonia, 2010–2014

		Relative survival ratio (%)					
		Total		Men		Women	
Cancer site	ICD-10	1-year	5-year	1-year	5-year	1-year	5-year
All sites	C00–96	**75**	**61**	**72**	**58**	**78**	**64**
All sites, excl. other skin	C00–96, excl. C44	**71**	**54**	**69**	**53**	**73**	**56**
Mouth and pharynx	C00–14	**63**	**38**	**59**	**32**	**76**	**55**
Oesophagus	C15	**32**	**9**	**34**	**11**	**27**	**6**
Stomach	C16	**45**	**26**	**45**	**25**	**47**	**29**
Colon	C18	**74**	**56**	**74**	**54**	**74**	**57**
Rectum	C19–21	**77**	**54**	**76**	**52**	**77**	**57**
Liver	C22	**19**	**5**	**22**	**4**	**14**	**5**
Gallbladder, bile ducts	C23–24	**40**	**16**	**46**	**24**	**36**	**11**
Pancreas	C25	**20**	**5**	**21**	**5**	**20**	**5**
Larynx	C32	**80**	**64**	**80**	**63**	**75**	**66**
Lung and trachea	C33–34	**36**	**14**	**34**	**13**	**40**	**17**
Skin melanoma	C43	**91**	**79**	**88**	**74**	**94**	**83**
Other skin	C44	**101**	**103**	**102**	**105**	**101**	**101**
Soft tissues	C48–49	**70**	**51**	**71**	**49**	**70**	**52**
Breast	C50	**94**	**79**	**96**	**86**	**94**	**79**
Cervix uteri	C53					**84**	**67**
Corpus uteri	C54					**91**	**78**
Ovary	C56					**79**	**45**
Prostate	C61			**97**	**91**		
Testis	C62			**97**	**95**		
Kidney	C64	**79**	**66**	**78**	**65**	**80**	**67**
Bladder and urinary tract	C65–68	**78**	**61**	**78**	**60**	**77**	**64**
Brain and central nervous system	C70–72	**42**	**19**	**46**	**19**	**38**	**18**
Thyroid	C73	**92**	**89**	**89**	**78**	**93**	**91**
Hodgkin lymphoma	C81	**88**	**83**	**88**	**79**	**87**	**87**
Non-Hodgkin lymphoma	C82–85/96	**74**	**57**	**75**	**60**	**72**	**54**
Multiple myeloma	C90	**61**	**34**	**63**	**39**	**60**	**30**
Leukaemia	C91–95	**69**	**49**	**75**	**50**	**62**	**48**

1. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006;260:103–17.
2. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda, MD: End Results Evaluation Section, National Cancer Institute; 1959.
3. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004;40:326–35.
4. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004;40:2494–501.